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Case Report
Ossifying Fibromyxoid Tumor: A Rare Subcutaneous
Tumor
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The following case study demonstrates a 26-year-old male that presented to the dermatology clinic with an enlarging, raised skin nodule located on the left inferior lateral lower back.
The patient reported it had persisted for two years, and he had not received prior treatment. He noted a family history of nonmelanoma skin cancer but had no other dermatological issues in the past. Physical examination revealed a pink, firm and well-circumscribed
subcutaneous mass with a prominent follicular pore. It was assumed the lesion was an epidermal inclusion cyst, and surgical excision was performed. Histopathology revealed lobules
of epithelioid cells with indistinct cytoplasm in a fibromyxoid hyalinized matrix surrounded
by lamellar bone and a collagenous pseudocapsule. Immunohistochemical staining showed
moderate desmin immunoreactivity and negative immunoreactivity for CD34, S-100, EMA,
actin and pancytokeratin. Based on the findings, a diagnosis of ossifying fibromyxoid tumor
was made. Given the uncertain biological potential of this lesion, re-excision was performed.
No residual tumor was identified on repeat pathological evaluation. The patient was scheduled for close follow-up to survey for recurrence or possible metastasis.
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Introduction

Ossifying fibromyxoid tumors (OFMTs) are
rare, soft tissue neoplasms that develop in the
subcutaneous layer of the skin. They were first
described in 1989 by Enzinger et al. in an article detailing 59 cases of a histologically unique
neoplasm.1 Histologically, they are characterized
by lobulated chords of bland, round cells organized in a fibromyxoid hyaline matrix with a peripheral shell of woven bone.2 Although OFMTs
can present in all age groups, they usually arise
in adults with a median age of 50, with a slight
predilection towards males (1.5:1).3 Clinically,
an OFMT tends to present as a small, painless
mass that persists over years most commonly
arising on the extremities. Most OFMTs are
benign and can be treated with excision; however, local recurrence has been seen in 17% of
cases. Furthermore, malignant OFMTs have
been identified in 5% of cases and have a meta-

static potential of 60%.3 The cellular origin of
these tumors is still unknown, although the
neuroectoderm is suspected in light of cyotarchitectural findings and positive staining to
markers such as S100, desmin, CD56, CD99 and
neurofilament.4 This case study aims to demonstrate an exemplary presentation, work-up
and management of an OMFT in order to shed
further light on these rare tumors as well as
to consider the origin of development in these
patients.

Case Presentation

A 26-year-old male presented to our dermatology clinic for a chief complaint of a skin lesion
located on his left inferior lateral lower back. He
reported that the lesion was enlarging, painful
and hard to the touch. Nothing had improved
or worsened the lesion. He received no treatment for this lesion in the past. Physical exam-
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Figure 1. Clinical image demonstrating a 2.3 x 2.0 cm subcutaneous nodule.
ination revealed a 2.3 x 2.0 cm painful subcutaneous nodule. (Figure 1) Initial assessment of
the skin lesion was an epidermal inclusion cyst,
and the patient elected to undergo surgical
excision. During surgical excision, it was noted
that the lesion had a different consistency than
an epidermal inclusion cyst, a fact that raised
concern for an odd neoplasm. The specimen
was submitted for dermatopathological evaluation.
Upon evaluation, the diagnosis of ossifying
fibromyxoid tumor was given. The patient
returned for re-excision, which on pathology
demonstrated dermal scar. The patient recovered well from surgery and therefore, was
scheduled for routine follow-up. Over 1.5 years
later, the patient does not report recurrence.

Pathology Report

The specimen was received in formalin and
consisted of a portion of skin measuring 3.0
x 2.0 x 1.5 cm and a firm subepidermal mass
measuring 1.3 x 1.0 cm. The mass was composed predominantly of sheets of vague
lobules of epithelioid cells, with indistinct
cytoplasm, set within a fibromyxoid to hyalinized matrix. The cells were relatively monomorphous. Neither atypical mitotic activity
nor necrosis was identified. The tumor was
surrounded by a “partial shell” of lamellar bone
as well as a collagenous pseudocapsule. (Figure
2) The metaplastic bone was normal in appearance and lacked atypical cytologic features.
(Figure 3) The lesional cells were moderately
immunoreactive for desmin. (Figure 4) These
cells failed to demonstrate immunoreactivity

Figure 2. H&E at 10x demonstrates lobules of epithelioid cells set within a fibromyxoid matrix surrounded by a “partial shell” of lamellar bone as well as a collagenous pseudocapsule.
274

Guerra et al. (2021) 2:4. https://doi.org/10.36518/2689-0216.1288

Figure 3. H&E at 100x demonstrates relatively monomorphous, epithelioid cells with indistinct cytoplasm set within a fibromyxoid to hyalinized matrix. Neither atypical mitotic activity nor necrosis was identified.
for CD34, helping to exclude a vascular lesion,
such as an angiomyxoma. Other negative
markers included S-100, pancytokeratin, EMA
and actin. Colloidal iron staining confirmed
the presence of subtle background mucin. By
evaluable features, the lesion was predicted
to be benign. Other than high cellularity, other
poor prognostic features were absent. No
high-grade nuclear atypia, high mitotic count
(>2/50 per high power field [HPF]), or infiltrative growth were identified. There is no reliably
distinguishing immunoprofile for this lesion.
The diagnosis of an OFMT was reached at the
conclusion of histopathological evaluation.
Although the features did not meet the criteria

for malignancy, there was some uncertainty of
biologic potential, and thus, conservative re-excision to ensure complete removal was advised.
Molecular studies were not preformed.

Discussion

OFMTs are a unique mesenchymal tumor that
can mimic other dermatological disorders and
go undiagnosed in many patients. According to
the Folpe and Weiss classification model, there
are typical, atypical and malignant OFMTs. A
typical OFMT is histologically characterized by
low nuclear grade, low cellularity and a mitotic rate <2/50 per HPF. By contrast, malignant OFMTs possess high nuclear grade, high
cellularity and mitotic activity >2/50 per HPF.

Figure 4. CImmunostain showing moderate immunoreactivity for desmin.
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Atypical OFMTs differ from typical OFMTs in
architectural and cytologic features; however, they do not meet the proposed criteria for
malignancy.5 One of the most useful staining
markers for OFMTs is S-100, which has been
identified on average in 75% of cases. Another
common marker is desmin, identified in about
25% of cases.3 Additionally, some studies note
neurofilament staining presence in over 80% of
cases.6 A few other stains that can be used include smooth muscle actin, pancytokeratin and
epithelial membrane antigen. Immunohistochemistry has identified some similarities and
differences between nonmalignant and malignant OFMTs. Compared to typical OFMTs,
malignant tumors are more frequently positive
for pancytokeratin, EMA and actin, and less frequently positive for S-100 and desmin.7 Given
the pathology report for this case, the lesion
did not meet malignant criteria. However, typical OFMTs do have metastatic potential (found
in 4% of cases). Additionally, these lesions
can be persistent and bothersome for many
patients. As was performed in this case, local
excision with negative margins is the typical
treatment for OFMTs. Non-malignant OFMTs
have a recurrence rate of about 8%, and thus,
close post-surgical surveillance is necessary so
that new lesions can be identified and treated.
In addition to excision, adjuvant radiation may
be utilized for certain cases with malignant
features. Chemotherapy may be considered if
there is extensive metastasis.3
Molecular studies have provided useful insight
to the molecular drivers of these neoplasms, as
well as possible lines of differentiation. PHF-1
gene rearrangement on 6p21 has been found
in up to 80% of tumors in studied case series.8
This gene encodes a protein that controls
embryonic stem cell differentiation via interaction with the protein associated with the
polycomb-repressive complex 2 gene (PRC2),
ultimately governing changes in chromatin
structure during fetal development.3 Furthermore, fluorescence in situ hybridization studies
have demonstrated mosaic INI-1 (integrase
interactor 1) loss that was identical in both
histologically typical and malignant OFMTs.7
Furthermore, OMFTs have shown upregulation
of EAAT4 and MUC4 protein expression, and
downregulation of PMP22 and MYEF2.9 Although the origin of these tumors is unknown,
there are some leads based on immunological
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and histological findings. Schwannian origin
has been cited as a possible precursor in light
of histological findings of replicated external
laminas and S-100 expression. However, PMP22
and MYEF2 are usually upregulated in nerve
sheath myxomas and schwannomas.9 Cartilaginous differentiation is also possible given
cytoarchitectural findings of irregular borders
with short processes and intracellular microfilaments, as well as S-100 positivity and weak
collagen II expression.9 Myoepithelial origin can
also be argued as they share certain low power
microscopic characteristics such as lobularity,
epithelioid cells and chondromyxoid stromas.
However, cytokeratin, smooth muscle actin and
SOX-10 are relatively infrequent markers found
in OFMTs compared to myoepithelial tumors.3
Lastly, neuronal cell origin is argued on the basis of prominent neurofilament staining, as well
as proteomic markers such as katanin, a neuron
microtubule protein, and versican, a neuron-associated glycoprotein. Nonetheless, the origin
remains unclear, and more research is warranted to unveil the exact line of differentiation of
these tumors.

Conclusion

OFMTs represent a group of mesenchymal neoplasms of unknown origin with certain features
used to aid in identification. However, classic
immunohistochemical markers such as S-100,
desmin and others employed may not always
be expressed. Furthermore, other tumors share
immunological and cytoarchitectural features
with OFMTs such as myoepithelial neoplasms,
epithelioid schwannomas and fibromyxoid
sarcomas, to name a few. Thus, strong clinical
suspicion must be utilized in combination with
the diagnostic tools available. Although rare
and usually benign, certain OFMTs can possess
histologically malignant features and have the
potential to metastasize and be life threatening. Close clinical surveillance is crucial in these
patients not only to identify and treat recurrences, but also to monitor for signs of metastatic lesions.
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